Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemaQuest Pharmaceuticals, a developer of small molecule therapeutics based on its proprietary SCFAD technologies, has concluded patient recruitment in a Phase 2 trial evaluating HQK-1001 as a treatment for sickle cell disease.
Subscribe to our email newsletter
The multi-dose randomized Phase 2 study enrolled approximately 52 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon.
The study aims to investigate the safety and tolerability of HQK-1001.
HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine.